PubMed Gruchlik A, Jurzak M, Chodurek E, Dzierewicz Z (2014)
PubMed, Minalyan, Artem, et al
Nephrotoxicity of anticancer drugs--an underestimated problem
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohns disease
Common side effects (minimal) Most people: No side effects GHK-Cu extremely well-tolerated Natural peptide (found in body) Minimal adverse effects Possible minor effects: Injection site stinging (common, harmless) Minor bruising at injection sites Slight blue tint to injection site (copper, temporary) Mild headache (rare) Managing side effects: Stinging: Inject slowly, warm peptide to room temp Bruising: Rotate sites, proper technique Blue tint: Normal, fades within days Headache: Hydrate well, reduce dose Contraindications and cautions Avoid if: Pregnancy or breastfeeding (no data) Active cancer (theoretical copper concerns) Wilson's disease (copper metabolism disorder) Hemochromatosis (iron overload, copper caution) Use caution with: Copper supplements (avoid taking both) High copper foods (monitor intake) Liver disease (copper metabolism) Generally safe for: All ages (adults) Men and women Long-term use Most health conditions Copper toxicity concerns Is copper in GHK-Cu dangerous
Redox reactions typically utilize the biologically accessible oxidization states of the metal core to transfer electrons to naturally occurring substrates that are essential for the cancer cell metabolism and therefore induce cell death
